| First Author | Lu J | Year | 2021 |
| Journal | EMBO Rep | Volume | 22 |
| Issue | 6 | Pages | e52013 |
| PubMed ID | 33998138 | Mgi Jnum | J:307406 |
| Mgi Id | MGI:6711921 | Doi | 10.15252/embr.202052013 |
| Citation | Lu J, et al. (2021) TRPV1 sustains microglial metabolic reprogramming in Alzheimer's disease. EMBO Rep :e52013 |
| abstractText | As the brain-resident innate immune cells, reactive microglia are a major pathological feature of Alzheimer's disease (AD). However, the exact role of microglia is still unclear in AD pathogenesis. Here, using metabolic profiling, we show that microglia energy metabolism is significantly suppressed during chronic Abeta-tolerant processes including oxidative phosphorylation and aerobic glycolysis via the mTOR-AKT-HIF-1alpha pathway. Pharmacological activation of TRPV1 rescues Abeta-tolerant microglial dysfunction, the AKT/mTOR pathway activity, and metabolic impairments and restores the immune responses including phagocytic activity and autophagy function. Amyloid pathology and memory impairment are accelerated in microglia-specific TRPV1-knockout APP/PS1 mice. Finally, we showed that metabolic boosting with TRPV1 agonist decreases amyloid pathology and reverses memory deficits in AD mice model. These results indicate that TRPV1 is an important target regulating metabolic reprogramming for microglial functions in AD treatment. |
